ALK and lung neuroendocrine neoplasm: Furthermore, the dual fusion of MRPL13-ALK and PPP1-CB-ALK is related to the acquired drug resistance of high-grade first-line chemotherapy drugs for lung neuroendocrine tumors with EGFR mutation [3].